Teplizumab
From Wikipedia, the free encyclopedia
Teplizumab is a monoclonal antibody which is used as an immunosuppressive drug. Teplizumab is a humanized Fc-engineered monoclonal antibody also known as MGA031 and hOKT3γ1(Ala-Ala).[1][2]
It targets at protecting the remaining beta cells in newly diagnosed T-1 diabetics. It has been used experimentally in type 1 diabetes mellitus,[3] but "these agents [i. e. anti-CD3-antibodies] alone do not restore normal glucose control".[4]
Eli Lilly licensed the drug back in 2007 from MacroGenics with a $41 million upfront and a billion dollars pledged for milestones.
It is in Phase-3 clinical trials for Type-1 DM. One-year data from one phase III trial was disappointing.[5]
[edit] See also
[edit] References
- ^ Woodle ES, Bluestone JA, Zivin RA, Jolliffe LK, Auger J, Xu D, Thistlethwaite JR (June 1998). "Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience". Transplant. Proc. 30 (4): 1369–70. doi:10.1016/S0041-1345(98)00278-4. PMID 9636555. http://linkinghub.elsevier.com/retrieve/pii/S0041134598002784.
- ^ Brown WM (April 2006). "Anti-CD3 antibody MacroGenics Inc". Curr Opin Investig Drugs 7 (4): 381–8. PMID 16625825.
- ^ Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA (June 2005). "A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes". Diabetes 54 (6): 1763–9. doi:10.2337/diabetes.54.6.1763. PMID 15919798. http://diabetes.diabetesjournals.org/cgi/pmidlookup?view=long&pmid=15919798.
- ^ Kaufman A, Herold KC (May 2009). "Anti-CD3 mAbs for treatment of type 1 diabetes". Diabetes/metabolism Research and Reviews 25 (4): 302–6. doi:10.1002/dmrr.933. PMID 19319985.
- ^ "MacroGenics and Lilly Ponder Future of Diabetes mAb after Phase III Flop". 21 Oct 2010. http://www.genengnews.com/gen-news-highlights/macrogenics-and-lilly-ponder-future-of-diabetes-mab-after-phase-iii-flop/81244098/.
[edit] External links
|
|
|
| Immune system ("-l(i[m])-") |
|
Human ("-limu-")
|
|
|
|
Mouse ("-limo-")
|
|
|
|
|
|
|
|
|
|
|
|
Chimeric + humanized
("-lixizu-")
|
|
|
|
| Interleukin ("-k(i[n])-") |
|
Human ("-kinu-")
|
|
|
|
Humanized ("-kizu-", "-kinzu-")
|
|
|
|
| Inflammatory lesions ("-les-") |
|
|
|
|
|
|
|
|
Intracellular
(initiation) |
|
|
Intracellular
(reception) |
|
|
| Extracellular |
|
|
|
|
|
Serum target
(noncellular)
|
|
|
|
Cellular target
|
|
|
|
Unsorted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(what is this?) (verify)
